OYAGEN INC has a total of 18 patent applications. It increased the IP activity by 0.0%. Its first patent ever was published in 2007. It filed its patents most often in WIPO (World Intellectual Property Organization), United States and Canada. Its main competitors in its focus markets pharmaceuticals, measurement and biotechnology are GILLIES MCINDOE RES INSTITUTE, HEBEI JUJING PHARMACEUTICAL CO LTD and JIANGSU ZEYUN PHARMACEUTICAL CO LTD.
# | Country | Total Patents | |
---|---|---|---|
#1 | WIPO (World Intellectual Property Organization) | 6 | |
#2 | United States | 5 | |
#3 | Canada | 3 | |
#4 | EPO (European Patent Office) | 3 | |
#5 | Australia | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Measurement | |
#3 | Biotechnology |
# | Technology | |
---|---|---|
#1 | Medical preparations | |
#2 | Therapeutic chemical compounds | |
#3 | Analysing materials | |
#4 | Peptides |
# | Name | Total Patents |
---|---|---|
#1 | Smith Harold C | 16 |
#2 | Bennett Ryan P | 15 |
#3 | Jahrling Peter | 4 |
#4 | Bennett Ryan | 2 |
#5 | Smith Harold | 2 |
#6 | Prohaska Kimberly | 1 |
#7 | Zhang Hui | 1 |
Publication | Filing date | Title |
---|---|---|
EP3565554A1 | Compounds, compositions, and methods for treating human immunodeficiency virus | |
US2020188404A1 | Methods of treating and inhibiting ebola virus infection | |
WO2015134854A2 | Small molecule vif dimerization antagonists as anti-hiv agents and for use as hiv/aids therapeutics | |
US2016143900A1 | Camptothecin derivatives as anti-HIV agents and methods of identifying agents that disrupt Vif self-association | |
WO2014186423A1 | Combination therapy for treating hiv and aids | |
EP2903611A1 | Small molecules as anti-hiv agents that disrupt vif self-association and methods of use thereof |